Autologous Hematopoietic Stem Cell Transplant for the Treatment of Refractory Myasthenia Gravis with Anti-Muscle Specific Kinase Antibodies.

We describe 3 patients with anti-MuSK MG treated with HSCT, all of whom became symptom free from MG with a tolerable side effect profile. In patients with severe refractory anti-MuSK MG, it may be reasonable to consider HSCT. This article is protected by copyright. All rights reserved.